NASDAQ : GRI

GRI Bio, Inc.

$1.47 USD

-$0.08 (-5.16%)

Volume
32.65K
Average Volume
63.24K
Market Capitalization
$132.05K
P/E Ratio
-0.02
Dividend Yield
0.00%
Price Target
Year High
$80.36
Year Low
$1.36
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$14.21
Company Overview

NASDAQ

W. Marc Hertz

Biotechnology

Healthcare

GRI

4

US

USD

619 400 1170

3622AW502

0001824293

Liquidity Metrics

0.01

14.21

14.21

13.91

0.00

Sales & Valuation

-$

0.00

0.17

-0.01

-9.78

Profitability

-$121.8

-$11.96M

0.00%

0.00%

-199.52%

-96.20%

P/E Metrics

-0.02

0.00

0.00

Analyst Price Target & Rating

Neutral

3/5

2 Analysts

%

Financial Health Scores

-8.60

1/9

$10.48M

$11.34M

$794K

-$10.92M

Key Metrics (TTM)

-$10.86M

0.00

0.99

14.21

-199.52%

-103.07%

-597.94%

-9191.76%

-27649 days

Company Executives
Name Title
Vipin Kumar Co-Founder & Chief Scientific Officer
W. Marc Hertz Co-Founder, Chief Executive Officer, President & Director
Leanne Kelly Chief Financial Officer & Corporate Secretary
Albert Agro Co-Founder & Chief Medical Officer
Poll Results

No votes yet today — be the first to share your view!

About GRI Bio, Inc. (NASDAQ:GRI) Stock

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio ... , Inc. was founded in 2009 and is based in LA Jolla, California.

Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact

2026-08-05 10:00:00

Ingevity Corporation (NYSE: NGVT) today announced it has published its [url="]2025 Sustainability Report[/url] featuring the company's advanced materials and tec

Ingram Micro Releases 2025 Sustainable Impact Report

2026-08-03 12:00:00

Ingram Micro today released its 2025 Sustainable Impact Report, detailing the company's progress made through 2025 to reduce carbon emissions, advance zero-wast

Williams Improves on Key Sustainability Metrics Amid Rising Energy Demand

2026-07-30 10:00:00

Williams (NYSE: WMB) today released its 2025 Sustainability Report, highlighting its environmental, safety and operational performance amid rapidly growing dema

Banner Bank Releases New Corporate Responsibility Report

2026-07-14 14:00:00

Today, Banner Bank released its 2025 Corporate Responsibility Report. The report identifies ongoing practices and recent accomplishments that contribute to crea

Asbury Automotive Group Named in TIME America's Best Companies 2026 List

2026-07-09 09:00:00

Asbury Automotive Group, Inc. (NYSE: ABG), one of the largest automotive retail and service companies in the U.S, is proud to be recognized on TIME's list of A

Luxshare Precision Releases 2025 Sustainability Report

2026-06-23 04:00:00

Luxshare Precision Releases 2025 Sustainability Report PR Newswire NEW YORK, June 23, 2026

CROWN HOLDINGS ANNOUNCES PUBLICATION OF ITS 2025 SUSTAINABILITY REPORT "DELIVERING SUSTAINABILITY", HIGHLIGHTING KEY MILESTONES AND PROGRESS TOWARD 2030 GOALS

2026-06-22 12:00:00

CROWN HOLDINGS ANNOUNCES PUBLICATION OF ITS 2025 SUSTAINABILITY REPORT "DELIVERING SUSTAINABILITY", HIGHLIGHTING KEY MILESTONES AND PROGRESS TO

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

2026-06-18 08:31:00

Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity

Frequently Asked Questions

What is the current GRI Bio, Inc. (GRI) stock price?

GRI Bio, Inc.(NASDAQ:GRI) stock price is $1.47 in the last trading session. During the trading session, GRI stock reached the peak price of $80.36 while $1.36 was the lowest point it dropped to. The percentage change in GRI stock occurred in the recent session was --5.16% while the dollar amount for the price change in GRI stock was -$0.08.

GRI's industry and sector of operation?

The NASDAQ listed GRI is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of GRI?

Vipin Kumar | Co-Founder & Chief Scientific Officer
W. Marc Hertz | Co-Founder, Chief Executive Officer, President & Director
Leanne Kelly | Chief Financial Officer & Corporate Secretary
Albert Agro | Co-Founder & Chief Medical Officer
|

How many employees does GRI have?

Number of GRI employees currently stands at 4. GRI operates from 2223 Avenida de la Playa, La Jolla, CA 92037, US.

Link for GRI official website?

Official Website of GRI is: https://www.gribio.com

How do I contact GRI?

GRI could be contacted at phone #619 400 1170 and can also be accessed through its website. GRI operates from 2223 Avenida de la Playa, La Jolla, CA 92037, US.

How many shares of GRI are traded daily?

The average number of GRI shares traded daily for last 3 months was 63.24K.

What is the market cap of GRI currently?

The market value of GRI currently stands at $132.05K with its latest stock price at $1.47